Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer’s disease: relevance for precision medicine in neurodegenerative diseases

A C T Acetylcholinesterase inhibitors (ChEI) are the global standard of care for the symptomatic treatment of Alzheimer's disease (AD) and show significant positive effects in neurodegenerative diseases with cognitive and behavioral symptoms.Although experimental and large-scale clinical evidence indicates the potential long-term List of Abbreviations: [ 18 F]-FDG, [ 18 F]-fluorodeoxyglucose; α7 nAChR, α7 nicotinic acetylcholine receptor subunit; Aβ, amyloid-β; Aβ42, 42-amino acid-long amyloid-β peptide; ACh, acetylcholine; AChE, acetylcholinesterase; AD, Alzheimer's disease; ADAM-17, a disintegrin and metalloproteinase 17; ADD, AD patients with dementia; ADME, absorption,